{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:12:25Z","timestamp":1777335145896,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWA.1160.18.200"],"award-info":[{"award-number":["NWA.1160.18.200"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs). Due to their specific actions, these kinds of interventions will only be effective in particular subsets of patients. To anticipate stratified application, we recently completed three bumetanide trials each focusing on different stratification strategies with the additional objective of deriving the most optimal endpoints. Here we publish the protocol of the post-trial access combined cohort study to confirm previous effects and stratification strategies in the trial cohorts and in new participants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method\/design<\/jats:title>\n                <jats:p>Participants of the three previous cohorts and a new cohort will be subjected to 6\u2009months bumetanide treatment using multiple baseline Single Case Experimental Designs. The primary outcome is the change, relative to baseline, in a set of patient reported outcome measures focused on direct and indirect effects of sensory processing difficulties. Secondary outcome measures include the conventional questionnaires \u2018social responsiveness scale\u2019, \u2018repetitive behavior scale\u2019, \u2018sensory profile\u2019 and \u2018aberrant behavior scale\u2019. Resting-state EEG measurements will be performed at several time-points including at Tmax after the first administration. Assessment of cognitive endpoints will be conducted using the novel Emma Tool box, an in-house designed battery of computerized tests to measure neurocognitive functions in children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study aims to replicate previously shown effects of bumetanide in NDD subpopulations, validate a recently proposed treatment prediction effect methodology and refine endpoint measurements.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT: 2020\u2013002196-35, registered 16 November 2020, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002196-35\/NL\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002196-35\/NL<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04033-8","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T10:10:44Z","timestamp":1657188644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol"],"prefix":"10.1186","volume":"22","author":[{"given":"Lisa","family":"Geertjens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianina","family":"Cristian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Haspels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Ramautar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert Jan","family":"van der Wilt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs","family":"Verhage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilgo","family":"Bruining","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"4033_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https:\/\/doi.org\/ezproxy.frederick.edu\/10.1176\/appi.books.9780890425596.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"4033_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neubiorev.2018.05.001","volume":"90","author":"JT Schulte","year":"2018","unstructured":"Schulte JT, Wierenga CJ, Bruining H. Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions. Neurosci Biobehav Rev. 2018;90:260\u201371.","journal-title":"Neurosci Biobehav Rev"},{"key":"4033_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fnins.2019.00310","volume":"13","author":"SC Kharod","year":"2019","unstructured":"Kharod SC, Kang SK, Kadam SD. Off-label use of bumetanide for brain disorders: an overview. Front Neurosci. 2019;13:310.","journal-title":"Front Neurosci"},{"issue":"5","key":"4033_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/1073858412438697","volume":"18","author":"Y Ben-Ari","year":"2012","unstructured":"Ben-Ari Y, Khalilov I, Kahle KT, Cherubini E. The GABA excitatory\/inhibitory shift in brain maturation and neurological disorders. Neuroscientist. 2012;18(5):467\u201386.","journal-title":"Neuroscientist"},{"issue":"9","key":"4033_CR5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrn920","volume":"3","author":"Y Ben-Ari","year":"2002","unstructured":"Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci. 2002;3(9):728\u201339.","journal-title":"Nat Rev Neurosci"},{"key":"4033_CR6","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1038\/tp.2012.124","volume":"2","author":"E Lemonnier","year":"2012","unstructured":"Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012;2:e202.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"4033_CR7","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1038\/tp.2017.10","volume":"7","author":"E Lemonnier","year":"2017","unstructured":"Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry. 2017;7(3):e1056.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"4033_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41398-020-0692-2","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Huang CC, Dai Y, Luo Q, Ji Y, Wang K, et al. Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA\/glutamate ratios. Transl Psychiatry. 2020;10(1):9.","journal-title":"Transl Psychiatry"},{"issue":"Pt 4","key":"4033_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/brain\/awr041","volume":"134","author":"R Nardou","year":"2011","unstructured":"Nardou R, Yamamoto S, Chazal G, Bhar A, Ferrand N, Dulac O, et al. Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital. Brain. 2011;134(Pt 4):987\u20131002.","journal-title":"Brain"},{"issue":"4","key":"4033_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cell.2010.10.016","volume":"143","author":"MC Marchetto","year":"2010","unstructured":"Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010;143(4):527\u201339.","journal-title":"Cell"},{"key":"4033_CR11","doi-asserted-by":"crossref","unstructured":"Deidda G, Parrini M, Naskar S, Bozarth IF, Contestabile A, Cancedda L. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. Nat Med. 2015;21(4):318-26.","DOI":"10.1038\/nm.3827"},{"issue":"2","key":"4033_CR12","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1542\/peds.2014-4133","volume":"136","author":"H Bruining","year":"2015","unstructured":"Bruining H, Passtoors L, Goriounova N, Jansen F, Hakvoort B, de Jonge M, et al. Paradoxical benzodiazepine response: a rationale for bumetanide in neurodevelopmental disorders? Pediatrics. 2015;136(2):e539\u201343.","journal-title":"Pediatrics"},{"issue":"1","key":"4033_CR13","doi-asserted-by":"publisher","first-page":"9195","DOI":"10.1038\/s41598-020-65500-4","volume":"10","author":"H Bruining","year":"2020","unstructured":"Bruining H, Hardstone R, Juarez-Martinez EL, Sprengers J, Avramiea AE, Simpraga S, et al. Measurement of excitation-inhibition ratio in autism spectrum disorder using critical brain dynamics. Sci Rep. 2020;10(1):9195.","journal-title":"Sci Rep"},{"issue":"1","key":"4033_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13229-020-00335-4","volume":"11","author":"DM van Andel","year":"2020","unstructured":"van Andel DM, Sprengers JJ, Oranje B, Scheepers FE, Jansen FE, Bruining H. Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. Mol Autism. 2020;11(1):30.","journal-title":"Mol Autism"},{"key":"4033_CR15","doi-asserted-by":"crossref","unstructured":"Sprengers JJ, van Andel DM, Zuithoff NPA, Keijzer-Veen MG, Schulp AJA, Scheepers FE, et al. Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial. J Am Acad Child Adolesc Psychiatry. 2021;60(7):865-876.","DOI":"10.1016\/j.jaac.2020.07.888"},{"issue":"21","key":"4033_CR16","first-page":"00251","volume":"S2451-9022","author":"EL Juarez-Martinez","year":"2021","unstructured":"Juarez-Martinez EL, Sprengers JJ, Cristian G, Oranje B, van Andel DM, Avramiea AE, et al. Prediction of behavioral improvement through resting-state EEG and clinical severity in a randomized controlled trial testing bumetanide in autism spectrum disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;S2451-9022(21):00251\u20132.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"4033_CR17","volume-title":"Social responsiveness scale","author":"J Constantino","year":"2012","unstructured":"Constantino J. Social responsiveness scale. 2nd ed; 2012.","edition":"2"},{"issue":"5","key":"4033_CR18","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10803-006-0213-z","volume":"37","author":"KS Lam","year":"2007","unstructured":"Lam KS, Aman MG. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37(5):855\u201366.","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"4033_CR19","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485\u201391.","journal-title":"Am J Ment Defic"},{"issue":"4","key":"4033_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5014\/ajot.52.4.283","volume":"52","author":"J Ermer","year":"1998","unstructured":"Ermer J, Dunn W. The sensory profile: a discriminant analysis of children with and without disabilities. Am J Occup Ther. 1998;52(4):283\u201390.","journal-title":"Am J Occup Ther"},{"key":"4033_CR21","unstructured":"Bouwmeester CJ. Single Case Designs. https:\/\/architecta.shinyapps.io\/SingleCaseDesignsv02\/ 2020."},{"issue":"4","key":"4033_CR22","doi-asserted-by":"publisher","first-page":"e001161","DOI":"10.1136\/bmjopen-2012-001161","volume":"2","author":"TJ Hoogeboom","year":"2012","unstructured":"Hoogeboom TJ, Kwakkenbos L, Rietveld L, den Broeder AA, de Bie RA, van den Ende CH. Feasibility and potential effectiveness of a non-pharmacological multidisciplinary care programme for persons with generalised osteoarthritis: a randomised, multiple-baseline single-case study. BMJ Open. 2012;2(4):e001161.","journal-title":"BMJ Open"},{"issue":"8","key":"4033_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","volume":"68","author":"R Jandoc","year":"2015","unstructured":"Jandoc R, Burden AM, Mamdani M, Levesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. J Clin Epidemiol. 2015;68(8):950\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"4033_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2190\/HFLM-ER1P-6J25-V0XD","volume":"18","author":"MJ Koehler","year":"1998","unstructured":"Koehler MJ, Lehrer R. Designing a hypermedia tool for learning about children\u2019s mathematical cognition. J Educ Comput Res. 1998;18(2):123\u201345.","journal-title":"J Educ Comput Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04033-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T10:15:16Z","timestamp":1657188916000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04033-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4033"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04033-8","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol has been reviewed and approved by the medical ethics committee of Utrecht, The Netherlands (\u2018Medisch ethische toetsingscommisie (METC) Utrecht\u2019) (reference number NL73520.041.20) and has been registered at the Eudra CT database (EudraCT: 2020\u2013002196-35). A protocol revision chronology and a trial registration data set are provided in appendices II and III respectively. Participants and their parents\/guardians will receive verbal and written information about the study. Separate information sheets and consent forms are available for parents\/guardians, children below the age of 12, children aged 12 to 16 and adolescents above the age of 16. The coordinating or principal investigator will obtain written informed consent from all participants before inclusion. Parents\/guardians provide written informed consent for children below the age of 12. Children and adolescents above the age of 12 provide their own written informed consent, combined with written informed consent by the parent\/guardian in case the participant is below the age of 16\u2009years.Monitoring will be conducted by the clinical research bureau (CRB) of the VUmc. The CRB is an independent party that monitors all WMO research at the VUmc. Study monitors will visit the study site at regular intervals to monitor the execution of the study. Monitors will have access to all documents that are needed to perform their task according to the ICH-GCP guidelines. Monitors will check whether requirements to conduct the study are met and study procedures are followed correctly, and will check the study site\u2019s documentation, the participants\u2019 source data, eCRF entries, and the correct maintenance of the Investigator Site File. Investigators will permit trial-related monitoring, audits, ERB reviews and regulatory inspections, providing direct access to source data and study documents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HB is shareholder of Aspect Neuroprofiles BV, which provides EEG-analysis services for clinical trials. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}